Lifecore Biomedical Operating Income Over Time
| LFCR Stock | 7.22 0.07 0.96% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lifecore Biomedical Performance and Lifecore Biomedical Correlation. Can Biotechnology industry sustain growth momentum? Does Lifecore have expansion opportunities? Factors like these will boost the valuation of Lifecore Biomedical. Expected growth trajectory for Lifecore significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Lifecore Biomedical demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (1.27) | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets | Return On Equity |
Understanding Lifecore Biomedical requires distinguishing between market price and book value, where the latter reflects Lifecore's accounting equity. The concept of intrinsic value - what Lifecore Biomedical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Lifecore Biomedical's price substantially above or below its fundamental value.
Understanding that Lifecore Biomedical's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lifecore Biomedical represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lifecore Biomedical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Lifecore Biomedical and related stocks such as BioAge Labs, Alpha Teknova, and Canopy Growth Corp Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOA | (41.2 M) | (41.2 M) | (41.2 M) | (41.2 M) | (35.2 M) | (38.5 M) | (29.6 M) | (110 M) | (40 M) | (40 M) | (40 M) | (40 M) | (40 M) | (48.4 M) | (78.2 M) | (70.4 M) | (73.9 M) |
| TKNO | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | 4.7 M | (12 M) | (49.7 M) | (35.6 M) | (26.1 M) | (23.5 M) | (24.7 M) |
| CGC | (26.9 K) | (21.4 K) | (64.6 K) | (931.7 K) | (6.7 M) | (2.7 M) | (15.2 M) | (78.9 M) | (553.6 M) | (1.7 B) | (1.2 B) | (1 B) | (2.6 B) | (228.7 M) | (117.1 M) | (6.7 M) | (7.1 M) |
| SGHT | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (24 M) | (32.2 M) | (51.5 M) | (84 M) | (57.3 M) | (50.5 M) | (45.5 M) | (47.8 M) |
| PRQR | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (16.5 M) | (27 M) | (39.6 M) | (40.5 M) | (36.3 M) | (57.4 M) | (42.4 M) | (57.2 M) | (65.2 M) | (31.9 M) | (30.5 M) | (27.4 M) | (28.8 M) |
| ACB | (1.2 K) | (330.8 K) | (402.9 K) | (306.5 K) | (4.4 M) | (4.6 M) | (11.2 M) | (95.8 M) | (318.3 M) | (465.8 M) | (282.8 M) | (231.4 M) | (207.2 M) | (46.5 M) | 4.9 M | 4.5 M | 4.7 M |
| IMMP | (1.9 M) | (18.5 M) | (15.1 M) | (13.3 M) | (13.9 M) | (61.5 M) | (9.4 M) | (11.7 M) | (20.4 M) | (16 M) | (31.7 M) | (33.9 M) | (77.7 M) | (88.1 M) | (126.4 M) | (113.8 M) | (108.1 M) |
| CVRX | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (11.5 M) | (26 M) | (42.5 M) | (43.1 M) | (59.5 M) | (51.3 M) | (53.8 M) |
| ACHV | (8.2 M) | (22.3 M) | (26 M) | (35.3 M) | (29.5 M) | (18.8 M) | (21.2 M) | (6.6 M) | (12.8 M) | (16.5 M) | (14.8 M) | (33.1 M) | (40.8 M) | (27.2 M) | (39.1 M) | (35.2 M) | (33.4 M) |
Lifecore Biomedical and related stocks such as BioAge Labs, Alpha Teknova, and Canopy Growth Corp Operating Income description
Operating Income is the amount of profit realized from Lifecore Biomedical operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Lifecore Biomedical is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Lifecore Biomedical | LFCR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 3515 Lyman Boulevard, |
| Exchange | NASDAQ Exchange |
null 7.22
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.